Patient NAME : Ms ANAMIKA GAYEN MONDAL
DOB/Age/Gender : 33 Y 11 M 25 D/Female Report STATUS : Final Report
Patient ID / UHID : ----------------------- Barcode NO : 12078052
Referred BY : Dr. S MONDAL. Sample Type : Serum
....
Sample Collected : Jun 09, 2025, 12:02 PM Report Date : Jun 12, 2025, 06:08 PM.
Test Description Value(s) Unit(s) Reference Range
Quadruple Marker Test- Beckman (Benetech)
AFP-Alpha Feto Protein 57.1 ng/mL
CLIA
uE3, unconjugated Estriol 2.5 ng/mL
CLIA
Beta HCG (Total) 32400 mIU/mL
CLIA
Inhibin A 455.5 pg/mL
CLIA
Comment :
Screen negative for Down syndrome, Edward syndrome and NTDs.
Interpretation:
Risk factor calculated by : Benetech PRA 3.4.0.3
Disorder Screen positive Cut off(ACOG2007) Remarks
1:250 for all age groups AFP MoM < or=0.74, HCG MoM > Confirmatory tests needed
Trisomy-21
or=2.06 UE3 MoM < or=0.75,Inhibin A: >or =1.77 under doctor'sadvise
1:100 for all age groups AFP MoM < or=0.65, HCG MoM < Maternal ultrasound needed
Trisomy-18
or=0.36 UE3 MoM < or=0.4 for confirmation
Open Neural Scan of Rachis
AFP MoM above 2.5
Tube Defect recommended
Note:
1. This is a screening test, results are based on statistical analysis of patient demographic, biochemical and USG data which simply indicate
a high or low risk category. Confirmation of screen positives is recommended by invasive diagnostic tests
2. The interpretive unit is MoM (Multiples of Median) which takes into account variables such as gestational age (ultrasound), m aternal weight,
race, insulin dependent Diabetes, multiple gestation, IVF (Date of Birth of Donor, if applicable), smoking & previous history of Down syndrome.
Accurate availability of this data for Risk Calculation is critical
3. Ideally all pregnant women should be screened for Prenatal disorders irrespective of maternal age. The test is valid between 14-22 weeks
of gestation, but ideal sampling time is between 15-20 weeks gestation.
Page 1 of 2
Patient NAME : Ms ANAMIKA GAYEN MONDAL
DOB/Age/Gender : 33 Y 11 M 25 D/Female Report STATUS : Final Report
Patient ID / UHID : ----------------------- Barcode NO : 12078052
Referred BY : Dr. S MONDAL. Sample Type : Serum
Sample Collected : Jun 09, 2025, 12:02 PM Report Date : Jun 12, 2025, 06:08 PM.
Test Description Value(s) Unit(s) Reference Range
Comments:
Second trimester screening for Prenatal disorders (Trisomy 21 & 18 and Open Neural Tube defects) is essential to identify those women at
sufficient risk for a congenital anomaly in the fetus to warrant further evaluation and follow up. Screening cutoffs are established by using MoM
values that maximize the detection rate and minimize false positives.
This is a risk estimation test and not a diagnostic test. An increased risk result does not mean that the fetus is affected and a low-risk result
does not mean that the fetus is unaffected. Reported risks should be correlated according to the absence/presence of sonograp hic markers
observed in the anomaly/malformation scan.
All lab results are subject to clinical interpretation by a qualified medical professional & this report is not subject to use for any medico-legal
purpose.
*** End Of Report ***
*This test is performed at an outsourced reference laboratory.
Page 2 of 2
QUADRUPLE MARKER (SECOND TRIMESTER SCREENING)
Patient Name: Ms ANAMIKA GAYEN MONDAL Code: 12078052
Race: INDIAN DOB: 16/06/1991
Physician: Reported: 12/06/2025
CLINICAL INFORMATION REMARKS
Estimation Method: from BPD of 50.5 mm on 09/06/2025 Down Syndrome
Age at Term: 34.3 years The risk of Down syndrome is LESS than the screening cut-off. No
EDD: 18/10/2025 follow-up is indicated regarding this result.
Gestation: Singleton Open Spina Bifida
Maternal History: IDDM(U), SMOKER(U), RH(U), VPA(U), The maternal serum AFP result is NOT elevated for a pregnancy of
SSRI(U), CBZ(U), IVF(N) this gestational age. The risk of an open neural tube defect is less
Gestational Age: 21 weeks 4 days than the screening cut-off.
Referring Lab #: --------------------- Trisomy 18
Specimen Code: 12078052 These serum marker levels are not consistent with the pattern seen
Specimen Date: 09/06/2025 in Trisomy 18 pregnancies. Maternal serum screening will detect
Received Date: 09/06/2025 approximately 60% of Trisomy 18 pregnancies.
Weight: 52.0 kg
Screening Status: Initial sample
Para / Gravida: 0 / 0
BIOCHEMISTRY CLINICAL RESULTS (at term)
MARKER RESULT MoM DS OSB T18
AFP 57.1 ng/mL 0.68
uE3 2.50 ng/mL 0.92 1:10
hCG 32400.0 mIU/mL 1.20
1 : 104 1 : 100
DIA 455.5 pg/ml 1.25 1:100 1 : 250
INTERPRETATION
Down Syndrome: Screen Negative 1:1000
Open Spina Bifida: Screen Negative
Trisomy 18: Screen Negative 1:10000
Prior Final Risk Prior Final Risk Prior Final Risk
1:490 1:540 1:1000 1:8900 1:4900 1:57900
